217 related articles for article (PubMed ID: 31732667)
21. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
22. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.
Falcon BL; Barr S; Gokhale PC; Chou J; Fogarty J; Depeille P; Miglarese M; Epstein DM; McDonald DM
Cancer Res; 2011 Mar; 71(5):1573-83. PubMed ID: 21363918
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study.
Feng H; Yang Z; Bai X; Yang M; Fang Y; Zhang X; Guo Q; Ning H
Int J Mol Med; 2018 Apr; 41(4):2099-2107. PubMed ID: 29344639
[TBL] [Abstract][Full Text] [Related]
24. Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model.
Salama M; Elhussiny M; Magdy A; Omran AG; Alsayed A; Ashry R; Mohamed W
Metab Brain Dis; 2018 Apr; 33(2):583-587. PubMed ID: 29080085
[TBL] [Abstract][Full Text] [Related]
25. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
26. The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.
Becker MN; Wu KJ; Marlow LA; Kreinest PA; Vonroemeling CA; Copland JA; Williams CR
Urol Oncol; 2014 Apr; 32(3):317-26. PubMed ID: 24054871
[TBL] [Abstract][Full Text] [Related]
27. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
28. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
[TBL] [Abstract][Full Text] [Related]
29. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
30. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
[TBL] [Abstract][Full Text] [Related]
31. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
32. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
33. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
34. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
36. PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway.
Zhang Z; Zhang G; Kong C; Gong D
Mol Med Rep; 2016 Jan; 13(1):333-8. PubMed ID: 26548560
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
[TBL] [Abstract][Full Text] [Related]
38. Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.
Hernández-Prat A; Rodriguez-Vida A; Juanpere-Rodero N; Arpi O; Menéndez S; Soria-Jiménez L; Martínez A; Iarchouk N; Rojo F; Albanell J; Brake R; Rovira A; Bellmunt J
Mol Cancer Res; 2019 Sep; 17(9):1931-1944. PubMed ID: 31160383
[TBL] [Abstract][Full Text] [Related]
39. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H
Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823
[TBL] [Abstract][Full Text] [Related]
40. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]